PT  - JOURNAL ARTICLE
AU  - Inge M M Lakeman
AU  - Florentine S Hilbers
AU  - Mar Rodríguez-Girondo
AU  - Andrew Lee
AU  - Maaike P G Vreeswijk
AU  - Antoinette Hollestelle
AU  - Caroline Seynaeve
AU  - Hanne Meijers-Heijboer
AU  - Jan C Oosterwijk
AU  - Nicoline Hoogerbrugge
AU  - Edith Olah
AU  - Hans F A Vasen
AU  - Christi J van Asperen
AU  - Peter Devilee
TI  - Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-<em>BRCA1/2</em> breast cancer families
AID  - 10.1136/jmedgenet-2019-106072
DP  - 2019 Sep 01
TA  - Journal of Medical Genetics
PG  - 581--589
VI  - 56
IP  - 9
4099  - http://jmg.bmj.com/content/56/9/581.short
4100  - http://jmg.bmj.com/content/56/9/581.full
SO  - J Med Genet2019 Sep 01; 56
AB  - Background The currently known breast cancer-associated single nucleotide polymorphisms (SNPs) are presently not used to guide clinical management. We explored whether a genetic test that incorporates a SNP-based polygenic risk score (PRS) is clinically meaningful in non-BRCA1/2 high-risk breast cancer families.Methods 101 non-BRCA1/2 high-risk breast cancer families were included; 323 cases and 262 unaffected female relatives were genotyped. The 161-SNP PRS was calculated and standardised to 327 population controls (sPRS). Association analysis was performed using a Cox-type random effect regression model adjusted by family history. Updated individualised breast cancer lifetime risk scores were derived by combining the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm breast cancer lifetime risk with the effect of the sPRS.Results The mean sPRS for cases and their unaffected relatives was 0.70 (SD=0.9) and 0.53 (SD=0.9), respectively. A significant association was found between sPRS and breast cancer, HR=1.16, 95% CI 1.03 to 1.28, p=0.026. Addition of the sPRS to risk prediction based on family history alone changed screening recommendations in 11.5%, 14.7% and 19.8 % of the women according to breast screening guidelines from the USA (National Comprehensive Cancer Network), UK (National Institute for Health and Care Excellence and the Netherlands (Netherlands Comprehensive Cancer Organisation), respectively.Conclusion Our results support the application of the PRS in risk prediction and clinical management of women from genetically unexplained breast cancer families.